Institution: | 1. The First Hospital of Harbin Medical University, Harbin 150001, China 2. The First Hospital of Harbin Medical University, Harbin 150001, China;Shijitan Hospital, The Ninth Clinical Medical College of Peking University, Beijing 100038, China 3. Shijitan Hospital, The Ninth Clinical Medical College of Peking University, Beijing 100038, China 4. Xuanwu Hospital, Capital University of Medical Sciences, Beijing 100053, China |
Abstract: | Arsenic trioxide (As2O3) is very effective for treatment of acute promyelocytic leukaemia (APL) but little can pass through the blood-brain-barrier
(BBB), which limits its use in the prevention and treatment of central nervous system leukaemia (CNSL). Before creating a
non-invasive method to help As2O3’s access, the safe and effective therapeutic concentration of As2O3 in the CNS ought to be known. The changes of apoptosis biomarkers, Ca2+]i and PKC activity of both leukaemia cells and human cortical neurons, were monitored before and after being treated with As2O3
in vitro with laser confocal microscopy and Western blot. NSE concentration, the neuron invasive biomarker, was monitored by enzyme
immunoassay (NSE-EIA). This study revealed that cortical neuron was more tolerable to As2O3 compared to NB4. 1.0 μmol / L As2O3 showed little influence on cortical neuron but effectively promoted apoptosis and induced differentiation of NB4. |